Historically neurodegenerative diseases, Alzheimer's disease (AD) in particular, have been viewed to be primarily caused and driven by neuronal mechanisms. Very recently, due to experimental, genetic, and epidemiologic evidence, immune mechanisms have entered the central stage and are now believed to contribute significantly to risk, onset, and disease progression of this class of disorders. Although immune activation of microglial cells may over time engage various signal transduction pathways, inflammasome activation, which represents a canonical and initiating pathway, seems to be one of the first responses to extracellular β-amyloid (Aβ) accumulation. Here we review the current understanding of inflammasome activation in AD.—Venegas, C., Heneka, M. T. Inflammasome-mediated innate immunity in Alzheimer's disease. FASEB J. 33, 13075–13084 (2019). www.fasebj.org.
CITATION STYLE
Venegas, C., & Heneka, M. T. (2019, December 1). Inflammasome-mediated innate immunity in Alzheimer’s disease. FASEB Journal. John Wiley and Sons Inc. https://doi.org/10.1096/fj.201900439
Mendeley helps you to discover research relevant for your work.